Please assess the completion status of the following clinical trial:

Trial Title: The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adults aged ≧65 years who had never received pneumococcal vaccine and quadrivalent influenza vaccine of 2015/2016 season~Exclusion Criteria:~* a sensitivity to pneumococcal and influenza vaccine~* received other inactivated vaccine within 14 days~* received other live vaccine within 28 days~* the presence of conditions known to impair pneumococcal vaccine response~* having malignant disease~* taking oral corticosteroids or immunosuppressive agent~* history of splenectomy~* history of an acute febrile illness or signs of severe acute illness at the time of vaccination~* other inappropriate condition to receive vaccination~* suffering an acute illness requiring antibiotics or steroids within the past month~* not expected to survive 12 months were also excluded

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simultaneous administration group (Type: ACTIVE_COMPARATOR): The subjects receive injections of pneumococcal vaccine and influenza vaccine simultaneously. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016 season.
- Sequential administration group (Type: ACTIVE_COMPARATOR): The subjects receive injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016.

Based on this trial design, predict the completion outcome and termination type (if applicable).